EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	951	(546/113,514/300).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/20 06:06
L2	197	l1 and azaindole	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/20 06:07
L3	3	l2 and CB	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/20 06:07

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 05:59:30 ON 20 SEP 2007

=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.21 | 0.21

FILE 'REGISTRY' ENTERED AT 05:59:40 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3
DICTIONARY FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10550663a.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
16
chain bonds :
8-10 10-11 11-12 12-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
6-9 8-9 10-11 11-12 12-16
exact bonds :
5-7 7-8 8-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 05:59:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1064 TO ITERATE

100.0% PROCESSED 1064 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 19324 TO 23236
PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 06:00:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22434 TO ITERATE

100.0% PROCESSED 22434 ITERATIONS 101 ANSWERS
SEARCH TIME: 00.00.01

L3 101 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 06:00:05 ON 20 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 19 Sep 2007 (20070919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 8 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:672998 CAPLUS
DOCUMENT NUMBER: 147:95703
TITLE: Preparation of 6-piperazinyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamides as histidine H3 receptor modulators for the treatment of obesity, diabetes and dyslipidemia
INVENTOR(S): Nettekoven, Matthias; Roche, Olivier
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.
SOURCE: PCT Int. Appl., 53pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007068641	A1	20070621	WO 2006-EP69390	20061206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007142358	A1	20070621	US 2006-634563	20061206
PRIORITY APPLN. INFO.:			EP 2005-112317 A	20051216

OTHER SOURCE(S): MARPAT 147:95703
GI



I



II

AB Title compds. I [wherein R1 = alkyl, cycloalkyl, (un)substituted Ph, etc.; R2, R3 = H, alkyl, (un)substituted Ph, etc.; R1 and R2 may link together to form a heterocyclic ring; R4 = (cyclo)alkyl] and pharmaceutically acceptable salts thereof were prepared as histidine H3 receptor modulators. For instance, substitution of 6-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid Et ester with 1-cyclopentylpiperazine followed by ester hydrolysis, and subsequent condensation with piperidine gave pyrrolopyridinecarboxamide II. This product exhibited binding affinity with a Ki value of 48.4 nM in an assay using HR3-CHO membranes. The invented compds. and their pharmaceutical compns. are potentially useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors, such as obesity, diabetes and dyslipidemia.

IT 942197-32-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of piperazinyl pyrrolopyridinecarboxamides as histidine H3 receptor modulators for treatment of obesity, diabetes and dyslipidemia)

RN 942197-32-2 CAPLUS

CN Methanone, [6-(4-cyclopentyl-1-piperazinyl)-1H-pyrrolo[2,3-b]pyridin-2-yl](4-methoxy-1-piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857600 CAPLUS

DOCUMENT NUMBER: 141:332183

TITLE: Preparation of azaindole derivatives (pyrrolopyridines), preparations thereof, uses thereof and compositions containing them

INVENTOR(S): Wei, Zhongyong; Dolaine, Regis; Walpole, Christopher; Yang, Hua

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087704	A1	20041014	WO 2004-SE472	20040326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1615922	A1	20060118	EP 2004-723882	20040326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2006522112	T	20060928	JP 2006-507989	20040326
US 2007027179	A1	20070201	US 2005-550663	20050926

PRIORITY APPLN. INFO.: SE 2003-908 A 20030331
WO 2004-SE472 W 20040326

OTHER SOURCE(S): MARPAT 141:332183
GI



I



II

AB Compds. of formula I [R1 = cycloalkylmethyl or tetrahydropyranylmethyl; X = divalent group that separates groups connected thereto by one or two saturated carbons; Ar = divalent aromatic group; R2 = (un)substituted-alkyl, -aryl or heteroaryl; R3 = carbon group connected to the six membered ring via a N atom or carbonyl group; Ra and Rb = R, halo, NO2, OR, CO2H, etc., wherein R = H or alkyl], as well as their pharmaceutically acceptable salts, and pharmaceutical compns. including the compds. are prepared Thus, e.g., II was prepared by substitution of 2-chloro-3-methyl-5-nitropyridine with cyclohexylmethylamine followed by nitro group reduction, amidation with trimethylacetyl chloride, and cyclocondensation with Me

4-ethoxybenzeneacetic acid ester. I possessed Ki values of 29-5852 nM in assays with human CB1 receptors. They are useful in therapy, in particular in the management of pain.

IT 773147-25-4P 773147-54-9P 773147-78-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrrolopyridines with analgesic activity)

RN 773147-25-4 CAPLUS
CN Carbamic acid, [1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773147-54-9 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-78-7 CAPLUS
CN Carbamic acid, [1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, 1-methylethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-42-5
CMF C26 H34 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 773147-21-0P 773147-22-1P 773147-23-2P
773147-24-3P 773147-26-5P 773147-27-6P
773147-28-7P 773147-29-8P 773147-30-1P
773147-31-2P 773147-32-3P 773147-33-4P
773147-34-5P 773147-35-6P 773147-36-7P
773147-37-8P 773147-38-9P 773147-39-0P
773147-40-3P 773147-41-4P 773147-42-5P
773147-43-6P 773147-44-7P 773147-45-8P
773147-46-9P 773147-47-0P 773147-48-1P
773147-49-2P 773147-50-5P 773147-51-6P
773147-52-7P 773147-53-8P 773147-55-0P
773147-56-1P 773147-57-2P 773147-59-4P
773147-61-8P 773147-63-0P 773147-64-1P
773147-65-2P 773147-67-4P 773147-69-6P
773147-70-9P 773147-72-1P 773147-74-3P
773147-76-5P 773147-79-8P 773147-80-1P
773147-81-2P 773147-82-3P 773147-83-4P
773147-84-5P 773147-85-6P 773147-86-7P
773147-87-8P 773147-88-9P 773147-89-0P
773147-90-3P 773147-91-4P 773147-92-5P
773147-93-6P 773147-94-7P 773147-95-8P
773147-96-9P 773147-97-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolopyridines with analgesic activity)

RN 773147-21-0 CAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 773147-22-1 CAPLUS
CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-23-2 CAPLUS
CN 3-Isoxazolecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-24-3 CAPLUS
CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-26-5 CAPLUS
CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-27-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-28-7 CAPLUS
CN Butanamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-29-8 CAPLUS
CN Urea, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 773147-30-1 CAPLUS
CN 1H-Imidazole-5-sulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,1-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-31-2 CAPLUS
CN 3-Isoxazolecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-32-3 CAPLUS
CN Benzamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-4-(dimethylamino)-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-33-4 CAPLUS
CN Benzoic acid, 4-[[[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 773147-34-5 CAPLUS
CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-2-nitro- (9CI) (CA INDEX NAME)



RN 773147-35-6 CAPLUS
CN Benzenesulfonamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-36-7 CAPLUS
CN Cyclobutanecarboxamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-37-8 CAPLUS
CN Benzamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,5-difluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-38-9 CAPLUS
CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-39-0 CAPLUS
CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)



RN 773147-40-3 CAPLUS
CN Urea, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 773147-41-4 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-42-5 CAPLUS
CN Carbamic acid, [1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 773147-43-6 CAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-44-7 CAPLUS

CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)



RN 773147-45-8 CAPLUS
CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-46-9 CAPLUS
CN Benzenesulfonamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-47-0 CAPLUS
CN Carbamic acid, [1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methyl-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 773147-48-1 CAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 773147-49-2 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)



RN 773147-50-5 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-51-6 CAPLUS
CN Cyclopropanecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-52-7 CAPLUS
CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-53-8 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-55-0 CAPLUS
CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-fluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-56-1 CAPLUS
CN Butanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-57-2 CAPLUS
CN Propanamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 773147-59-4 CAPLUS
CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773147-61-8 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(3-methoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-53-8
CMF C27 H35 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-63-0 CAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-21-0
CMF C28 H38 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-64-1 CAPLUS
CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-

pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-22-1
CMF C29 H39 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-65-2 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-50-5
CMF C28 H37 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-67-4 CAPLUS
CN Cyclopropanecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-51-6
CMF C28 H35 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-69-6 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-49-2
CMF C29 H39 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-70-9 CAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N',N'-diethyl-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-43-6
CMF C29 H40 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-72-1 CAPLUS
CN 3-Isoxazolecarboxamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-23-2
CMF C29 H34 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-74-3 CAPLUS
CN Benzamide, N-[1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2-fluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-55-0
CMF C31 H34 F N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-76-5 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,2-dimethyl-, mono(trifluoroacetate) (9CI)

(CA INDEX NAME)

CM 1

CRN 773147-41-4
CMF C27 H36 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-79-8 CAPLUS
CN Propanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-44-7
CMF C28 H38 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-80-1 CAPLUS
CN Butanamide, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-45-8
CMF C28 H38 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-81-2 CAPLUS
CN Urea, N-[1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-48-1
CMF C27 H37 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-82-3 CAPLUS
CN Benzenesulfonamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-35-6
CMF C29 H31 F2 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-83-4 CAPLUS

CN Cyclobutanecarboxamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-36-7
CMF C28 H35 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-84-5 CAPLUS
CN Benzamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,5-difluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-37-8
CMF C30 H31 F2 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-85-6 CAPLUS
CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-38-9
CMF C27 H35 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-86-7 CAPLUS
CN Propanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,2,2-trimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-39-0
CMF C28 H37 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-87-8 CAPLUS
CN Urea, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-40-3
CMF C27 H36 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-88-9 CAPLUS

CN Butanamide, N-[2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-56-1
CMF C28 H37 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-89-0 CAPLUS
CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-2,6-difluoro-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-26-5
CMF C28 H29 F2 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-90-3 CAPLUS
CN 2-Pyridinecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-27-6
CMF C28 H30 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-91-4 CAPLUS
CN Butanamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,3-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-28-7
CMF C27 H35 N3 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-92-5 CAPLUS
CN Urea, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-N'-(1-methylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-29-8
CMF C26 H34 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-93-6 CAPLUS
CN 1H-Imidazole-5-sulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,1-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-30-1
CMF C26 H31 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-94-7 CAPLUS
CN 3-Isoxazolecarboxamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-31-2
CMF C27 H30 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-95-8 CAPLUS
CN Benzamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-4-(dimethylamino)-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-32-3
CMF C31 H36 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-96-9 CAPLUS
CN Benzoic acid, 4-[[[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]methylamino]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-33-4
CMF C29 H31 N3 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 773147-97-0 CAPLUS
CN Benzenesulfonamide, N-[1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-methyl-2-nitro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 773147-34-5
CMF C28 H30 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 773148-01-9P 773148-02-0P 773148-06-4P
773148-07-5P 773148-08-6P 773148-10-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrrolopyridines with analgesic activity)

RN 773148-01-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 773148-02-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773148-06-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 773148-07-5 CAPLUS
CN Carbamic acid, [2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 773148-08-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 2-[(4-ethoxyphenyl)methyl]-N-methyl-1-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 773148-10-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-5-amine, 1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:796483 CAPLUS
DOCUMENT NUMBER: 139:292139
TITLE: Preparation of heteroarylalkanols as glucocorticoid mimetics for treatment of inflammatory, allergic, and proliferative diseases
INVENTOR(S): Bekkali, Younes; Betageri, Raj; Gilmore, Thomas A.; Cardozo, Mario G.; Kirrane, Thomas M.; Kuzmich, Daniel; Proudfoot, John Robert; Takahashi, Hidenori; Thomson, David; Wang, Ji; Zindell, Renee; Harcken, Christian Hanke Justus Joachim; Riether, Doris
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003082280	A1	20031009	WO 2003-US8901		20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2478156	A1	20031009	CA 2003-2478156		20030321
AU 2003218342	A1	20031013	AU 2003-218342		20030321
US 2004023999	A1	20040205	US 2003-394303		20030321
US 6903215	B2	20050607			
EP 1490062	A1	20041229	EP 2003-714339		20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003008784	A	20050111	BR 2003-8784		20030321
CN 1633296	A	20050629	CN 2003-807180		20030321
JP 2005527555	T	20050915	JP 2003-579818		20030321
NZ 535889	A	20060331	NZ 2003-535889		20030321
IN 2004DN02316	A	20050401	IN 2004-DN2316		20040810
US 2005059714	A1	20050317	US 2004-944615		20040917
NO 2004004031	A	20041019	NO 2004-4031		20040924
MX 2004PA09329	A	20050125	MX 2004-PA9329		20040924
US 2005282881	A1	20051222	US 2005-185349		20050720
ZA 200406225	A	20060531	ZA 2004-6225		20060317
US 2006189647	A1	20060824	US 2006-410408		20060425
PRIORITY APPLN. INFO.:			US 2002-367758P	P	20020326
			US 2002-431817P	P	20021209
			US 2003-442404P	P	20030124
			US 2003-394303	A1	20030321
			WO 2003-US8901	W	20030321
			US 2004-944615	A1	20040917
			US 2005-185349	A1	20050720

OTHER SOURCE(S): MARPAT 139:292139
GI



I



II



III

AB Title compds. I and II [wherein R1 = substituted (hetero)aryl; R2 and R3 = independently H or alkyl; or CR2R3 = cycloalkyl; R4 = (un)substituted alkyl, alkenyl, or alkynyl; R5 = substituted heteroaryl; and R6 (when present) = (un)substituted alkyl, alkenyl, alkynyl, carbocyclyl(alkyl), heterocyclyl(alkyl), (hetero)aryl(alkyl), arylhaloalkyl, carbocyclylalkenyl, heterocyclylalkenyl, or (hetero)arylalkenyl; and tautomers, prodrugs, solvates, or salts thereof] were prepared as glucocorticoid mimetics (no data). For example, 1,1,1-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methylpentan-2-one (multi-step preparation from Et trifluoropyruvate, 1-bromo-2-methylpropene, and 4-fluoroanisole given) was coupled with 2-methyl-5-phenylbenzoxazole using LDA in THF to afford III. I, II, and pharmaceutical compns. containing such compds. are useful for treating inflammatory, allergic, or proliferative disorders mediated by glucocorticoid receptor (GR) function (no data).

IT 609851-47-0P, 1,1,1-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-[(1H-pyrrolo[2,3-b]pyridin-2-yl)methyl]pentan-2-ol
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glucocorticoid mimetic; preparation of heteroarylalkanols as GR modulators for treatment of inflammatory, allergic, and proliferative diseases)

RN 609851-47-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-2-ethanol, α-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-α-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:356415 CAPLUS
DOCUMENT NUMBER: 138:368759
TITLE: Preparation of 2-acylindoles as tubulin polymerization inhibitors for the treatment of metastatic tumors
INVENTOR(S): Beckers, Thomas; Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus; Hufsky, Harald; Hockemeyer, Joerg; Vanhoefer, Udo
PATENT ASSIGNEE(S): Baxter Healthcare SA, Switz.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037861	A1	20030508	WO 2002-EP11883	20021024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10152306	A1	20030724	DE 2001-10152306	20011026
EP 1442015	A1	20040804	EP 2002-802302	20021024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516895	T	20050609	JP 2003-540143	20021024
PRIORITY APPLN. INFO.:			DE 2001-10152306 A	20011026
			WO 2002-EP11883 W	20021024

OTHER SOURCE(S): MARPAT 138:368759
GI



I



II



III

AB Title compds. I [R1 = H, alkylcarbonyl, e.g., acetyl, alkyl etc.; R2 = H, halo, CN, etc.; A = B, C, D = independently for a N or C with provisos; Y = electron pair, H, halo with provisos; X = O, S, NH, etc.] and their pharmaceutically acceptable salts were prepared For example, sodium hydroxide mediated deprotection of N-sulfone II, e.g., prepared from benzoyl chloride and 5-methoxy-1-(phenylsulfonyl)-1H-indole, afforded acylindole III. In tubulin polymerization inhibition studies, 8-examples of I exhibited IC50 values ranging from 0.53->10 μM, e.g., the IC50 value of acylindole III was 0.53 μM. Compds. I are claimed useful for the treatment of therapy-resistant and metastatic tumors.

IT 370580-89-5P 370580-90-8P 370580-91-9P
370580-92-0P 521309-89-7P 521309-90-0P
521309-91-1P 521309-92-2P 521310-04-3P
521310-05-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of acylindoles as tubulin polymerization inhibitors
for the treatment of metastatic tumors)

RN 370580-89-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-90-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-91-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 370580-92-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 521309-89-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy-2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 521309-90-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy-2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 521309-91-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-5-methoxy-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 521309-92-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy-1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 521310-04-3 CAPLUS
CN Methanone, (5-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 521310-05-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-acetyl-5-methoxy-2-(3,4,5-trimethoxybenzoyl)-, 7-oxide (9CI) (CA INDEX NAME)



IT 370581-48-9P 370581-49-0P 370581-50-3P
370581-51-4P 521309-94-4P 521309-95-5P
521309-96-6P 521309-97-7P 521309-98-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylindoles as tubulin polymerization inhibitors
for the treatment of metastatic tumors)
RN 370581-48-9 CAPLUS
CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-49-0 CAPLUS
CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-50-3 CAPLUS
CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 370581-51-4 CAPLUS
CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 521309-94-4 CAPLUS
CN Methanone, (2-methoxyphenyl)(5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 521309-95-5 CAPLUS
CN Methanone, (3-methoxyphenyl)(5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 521309-96-6 CAPLUS
CN Methanone, (2,4-dimethoxyphenyl)(5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)- (9CI) (CA INDEX NAME)



RN 521309-97-7 CAPLUS
CN Methanone, (5-methoxy-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 521309-98-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-acetyl-6-ethoxy-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:836852 CAPLUS
DOCUMENT NUMBER: 136:112229
TITLE: Synthetic 2-Aroylindole Derivatives as a New Class of Potent Tubulin-Inhibitory, Antimitotic Agents
AUTHOR(S): Mahboobi, Siavosh; Pongratz, Herwig; Hufsky, Harald; Hockemeyer, Joerg; Frieser, Markus; Lyssenko, Alexei; Paper, Dietrich H.; Buergermeister, Jutta; Boehmer, Frank-D.; Fiebig, Heinz-Herbert; Burger, Angelika M.; Baasner, Silke; Beckers, Thomas
CORPORATE SOURCE: Faculty of Chemistry and Pharmacy Institute of Pharmacy, University of Regensburg, Regensburg, D-93040, Germany
SOURCE: Journal of Medicinal Chemistry (2001), 44(26), 4535-4553
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:112229

AB A new class of simple synthetic antimitotic compds. based on 2-aroylindoles was discovered. (5-Methoxy-1H-2-indolyl)-phenylmethanone (I) as well as analogous 3-fluorophenyl- and 3-methoxyphenyl derivs. displayed high cytotoxicity of IC50 = 20 to 75 nM against the human HeLa/KB cervical, SK-OV-3 ovarian, and U373 astrocytoma carcinoma cell lines. The inhibition of proliferation correlated with the arrest in the G2/M phase of the cell cycle. In in vitro assays with tubulin isolated from bovine brain, in general antiproliferative activity correlated with inhibition of tubulin polymerization Thus, the antimitotic activity of 2-aroylindoles is explained by interference with the mitotic spindle apparatus and destabilization of microtubules. In contrast to colchicine, vincristine, nocodazole, or taxol, I did not significantly affect the GTPase activity of β-tubulin. Interestingly, selected compds. inhibited angiogenesis in the chorioallantoic membrane (CAM) assay. In xenograft expts., I was highly active after oral administration at 200 mg/kg against the human amelanocytic melanoma MEXF 989 in athymic nude

mice. We conclude, that 2-aroylindoles constitute an interesting new class of antitubulin agents with the potential to be clin. developed for cancer treatment.

IT 370581-48-9P 370581-49-0P 370581-50-3P
370581-51-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aroylindoles as tubulin-inhibitory antimitotic agents)

RN 370581-48-9 CAPLUS
CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-49-0 CAPLUS
CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-50-3 CAPLUS
CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 370581-51-4 CAPLUS
CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



IT 370580-89-5P 370580-90-8P 370580-91-9P
370580-92-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aroylindoles as tubulin-inhibitory antimitotic agents)

RN 370580-89-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-90-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-91-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 370580-92-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:816437 CAPLUS
DOCUMENT NUMBER: 135:352771
TITLE: (Hetero)indole derivatives, their preparation, pharmaceutical compositions, and their use as antitumor agents
INVENTOR(S): Beckers, Thomas; Baasner, Silke; Klenner, Thomas; Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus; Hufsky, Harald; Hockemeyer, Jorg; Fiebig, Heinz-Herbert; Burger, Angelika; Bohmer, Frank-D.
PATENT ASSIGNEE(S): Asta Medica A.-G., Germany
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082909	A2	20011108	WO 2001-EP4783	20010427
WO 2001082909	A3	20020314		
W: AT, AU, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, DZ, EE, ES, FI, GB, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LU, LV, MK, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, US, UZ, YU, ZA, AM, AZ, MD, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
DE 10020852	A1	20011031	DE 2000-10020852	20000428
DE 10102629	A1	20020725	DE 2001-10102629	20010120
CA 2407677	A1	20021028	CA 2001-2407677	20010427
EP 1276720	A2	20030122	EP 2001-947247	20010427
EP 1276720	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR				
BR 2001010414	A	20030211	BR 2001-10414	20010427
HU 200300480	A2	20030628	HU 2003-480	20010427
JP 2004501092	T	20040115	JP 2001-579784	20010427
EE 200200607	A	20040415	EE 2002-607	20010427
AU 783459	B2	20051027	AU 2001-68984	20010427
NZ 522246	A	20060127	NZ 2001-522246	20010427
NO 2002005150	A	20021216	NO 2002-5150	20021025
MX 2002PA10627	A	20040517	MX 2002-PA10627	20021028
IN 2002KN01342	A	20050311	IN 2002-KN1342	20021028
BG 107309	A	20030930	BG 2002-107309	20021125
HK 1054549	A1	20070223	HK 2003-105237	20030721

PRIORITY APPLN. INFO.:
DE 2000-10020852 A 20000428
DE 2001-10102629 A 20010120
WO 2001-EP4783 W 20010427

OTHER SOURCE(S): CASREACT 135:352771; MARPAT 135:352771
GI



I

AB The invention discloses indole and heteroindole derivs. I [R1 = H, C1-6

alkyl, C1-6 alkylcarbonyl, etc.; R2 = H, halo, cyano, etc.; R3-R6 = H, halo, nitro, etc.; A-D = C, N; Y = (un)substituted C6-14 aryl, etc.; X = O, S, NH, CHOH], and tautomers, stereoisomers, mixts. and salts thereof, as well as the production thereof and the use thereof for the treatment of tumors.

IT 370580-89-5P 370580-90-8P 370580-91-9P
370580-92-0P 370581-50-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(indole and heteroindole derivs. for antitumor agents, preparation, and pharmaceutical compns.)

RN 370580-89-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-90-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-91-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 370580-92-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370581-50-3 CAPLUS
CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



IT 370581-48-9P 370581-49-0P 370581-51-4P
370581-56-9P 370581-58-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(indole and heteroindole derivs. for antitumor agents, preparation, and pharmaceutical compns.)
RN 370581-48-9 CAPLUS
CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-49-0 CAPLUS
CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-51-4 CAPLUS
CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-56-9 CAPLUS
CN Methanone, (7-oxido-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 370581-58-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 1-acetyl-2-(3,4,5-trimethoxybenzoyl)-, acetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:795073 CAPLUS
DOCUMENT NUMBER: 135:331343
TITLE: Preparation of 1H-indol-2-yl aryl ketones and related compounds as antitumor agents
INVENTOR(S): Beckers, Thomas; Baasner, Silke; Klenner, Thomas; Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus; Hufsky, Harald; Hockemeyer, Joerg; Fiebig, Heinz-Herbert; Burger, Angelika; Boehmer, Frank-D.
PATENT ASSIGNEE(S): Asta Medica A.-G., Germany
SOURCE: Ger. Offen., 34 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10020852	A1	20011031	DE 2000-10020852	20000428
WO 2001082909	A2	20011108	WO 2001-EP4783	20010427
WO 2001082909	A3	20020314		

W: AT, AU, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, DZ, EE, ES, FI, GB, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LU, LV, MK, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, US, UZ, YU, ZA, AM, AZ, MD, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE, TR

US 2002091124	A1	20020711	US 2001-843139		20010427
CA 2407677	A1	20021028	CA 2001-2407677		20010427
EP 1276720	A2	20030122	EP 2001-947247		20010427
EP 1276720	B1	20061220			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR					
BR 2001010414	A	20030211	BR 2001-10414		20010427
HU 200300480	A2	20030628	HU 2003-480		20010427
JP 2004501092	T	20040115	JP 2001-579784		20010427
EE 200200607	A	20040415	EE 2002-607		20010427
AU 783459	B2	20051027	AU 2001-68984		20010427
NZ 522246	A	20060127	NZ 2001-522246		20010427
AT 348805	T	20070115	AT 2001-947247		20010427
US 2003158216	A1	20030821	US 2002-279123		20021024
NO 2002005150	A	20021216	NO 2002-5150		20021025
MX 2002PA10627	A	20040517	MX 2002-PA10627		20021028
IN 2002KN01342	A	20050311	IN 2002-KN1342		20021028
ZA 2002009137	A	20040618	ZA 2002-9137		20021111
BG 107309	A	20030930	BG 2002-107309		20021125
HK 1054549	A1	20070223	HK 2003-105237		20030721
PRIORITY APPLN. INFO.:			DE 2000-10020852	A	20000428
			DE 2001-10102629	A	20010120
			US 2001-843139	B1	20010427
			WO 2001-EP4783	W	20010427

OTHER SOURCE(S): MARPAT 135:331343

GI



I

AB Use of title compds. [I; R1 = H, alkylcarbonyl, alkylaminoalkyl, dialkylaminoalkyl, (hetero)cyclyl; R2 = H, halo, cyano, NO2, (substituted) alkyl, alkoxy, etc.; A-D = N, (substituted) C; R3-R6 = free electron pair if A-D = N, or H, halo, cyano, NO2, alkyl, etc. if A-D = C; Y = (substituted) aryl; X = O, S, NH, (H,OH)], for preparation of drugs for treatment of tumor illness in mammals is claimed. Thus, 5-methoxy-1H-indol-2-yl Ph ketone (general preparation given) showed antitumor activity with IC50 = 96.5 nM in rat glioma cell lines C6.

IT 370581-50-3P, (1H-Pyrrolo[2,3-b]pyridin-2-yl)(3,4,5-trimethoxyphenyl)methanone 370581-56-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indolyl aryl ketones and related compds. as antitumor agents)

RN 370581-50-3 CAPLUS

CN Methanone, 1H-pyrrolo[2,3-b]pyridin-2-yl(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 370581-56-9 CAPLUS
CN Methanone, (7-oxido-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



IT 370581-48-9P, (1H-Pyrrolo[2,3-b]pyridin-2-yl)(2-methoxyphenyl)methanone 370581-49-0P, (1H-Pyrrolo[2,3-b]pyridin-2-yl)(3-methoxyphenyl)methanone 370581-51-4P, (1H-Pyrrolo[2,3-b]pyridin-2-yl)(2,4-dimethoxyphenyl)methanone 370581-58-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolyl aryl ketones and related compds. as antitumor agents)

RN 370581-48-9 CAPLUS
CN Methanone, (2-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-49-0 CAPLUS
CN Methanone, (3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-51-4 CAPLUS
CN Methanone, (2,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl- (9CI) (CA INDEX NAME)



RN 370581-58-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-6-ol, 1-acetyl-2-(3,4,5-trimethoxybenzoyl)-, acetate (ester) (9CI) (CA INDEX NAME)



IT 370580-89-5P 370580-90-8P 370580-91-9P
370580-92-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolyl aryl ketones and related compds. as antitumor agents)

RN 370580-89-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-90-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(3-methoxybenzoyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-91-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 370580-92-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 2-(2,4-dimethoxybenzoyl)-1-(phenylsulfonyl)-
(9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:198231 CAPLUS
DOCUMENT NUMBER: 126:293275
TITLE: Synthesis of 2-substituted-1H-pyrrolo[2,3-b]pyridines: preparation of 7-azaolivacine analog and 7-azaindolopyridopyrimidine derivatives
AUTHOR(S): Desarbre, Eric; Coudret, Sandrine; Meheust, Cecile; Merour, Jean-Yves
CORPORATE SOURCE: Inst. Chimie Organique Analytique, Univ. d'Orleans, Orleans, F-45067, Fr.
SOURCE: Tetrahedron (1997), 53(10), 3637-3648
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB 2-Substituted-1H-pyrrolo[2,3-b]pyridines I (R = Me, 4-MeC6H4CHOH, 4-ClC6H4CHOH, etc.) have been prepared from 7-azaindole by lithiation followed by addition of various electrophiles. A 7-azaolivacine analog II and a pyrido[3',2':4,5]pyrrolo[1,2-c]pyrido[3,2-d]pyrimidine III have also been prepared

IT 189089-95-0P 189089-96-1P 189089-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolopyridines, azaolivacine analog, and azaindolopyridopyrimidine derivative)

RN 189089-95-0 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-4-[hydroxy[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 189089-96-1 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-2-methoxy-4-[[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 189089-97-2 CAPLUS
CN 3-Pyridinecarboxamide, N,N-diethyl-4-[1-hydroxy-1-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



IT 189089-84-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrrolopyridines, azaolivacine analog, and

azaindolopyridopyrimidine derivative)
RN 189089-84-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-2-methanol, α-(4-methoxyphenyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 05:59:30 ON 20 SEP 2007)

FILE 'REGISTRY' ENTERED AT 05:59:40 ON 20 SEP 2007
L1 STRUCTURE UPLOADED
L2 6 S L1
L3 101 S L1 FULL

FILE 'CAPLUS' ENTERED AT 06:00:05 ON 20 SEP 2007
L4 8 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.98	217.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

STN INTERNATIONAL LOGOFF AT 06:03:40 ON 20 SEP 2007